News

Aurobindo Pharma announced robust Q3FY26 results on February 10, 2026, with revenue up 8.4% to ₹8,646 crores, strong Europe growth, and key regulatory approvals for biosimilars through CuraTeQ Biologics.[4]

The U.S. FDA has initiated its PreCheck pilot program to expedite construction and regulatory review of domestic drug manufacturing facilities, prioritizing critical medications.

The European Medicines Agency has released its CHMP work plan for 2026, outlining key priorities for medicinal product evaluations and regulatory support across the EU pharmaceutical sector.

U.S. pharmaceutical companies, including 16 with Trump administration pricing agreements, raised list prices on 872 brand-name medications with a median 4% increase in early 2026, highlighting ongoing pricing dynamics in the industry.[2]

South Korean medtech firm Sky Labs has secured an exclusive deal with Japan's Otsuka Pharmaceutical to distribute its advanced ring-type blood pressure monitor CART BP pro in Japanese hospitals and clinics.

Acadia Pharmaceuticals announced a negative trend vote from EMA's CHMP on its Marketing Authorization Application for trofinetide in treating Rett Syndrome, with plans to request re-examination.

Bristol Myers Squibb has partnered with Microsoft to deploy FDA-cleared AI radiology tools via Precision Imaging Network, targeting earlier lung cancer detection in underserved U.S. communities.

Everest Medicines enters exclusive license agreement with Micot to commercialize innovative dual-targeting peptide MT1013 for Secondary Hyperparathyroidism in China and Asia-Pacific, excluding Japan.

The EU institutions have finalized political agreement on the Pharma Package, introducing revisions to data and market protection while mandating supply across member states.

Bristol Myers Squibb announced robust Q4 and full-year 2025 financial results today, driven by 16% growth in its immuno-oncology portfolio and key regulatory milestones.